Formycon will find out in June whether its FYB203 proposed biosimilar to Eylea (aflibercept) will receive US Food and Drug Administration approval, in the wake of the agency approving last month the first biosimilars to the world’s leading anti-VEGF brand to treat wet age-related macular degeneration.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?